Purple Biotech Announces IM1240 Data
Ticker: PPBT · Form: 6-K · Filed: Sep 4, 2025 · CIK: 1614744
Sentiment: neutral
Topics: biotech, drug-development, collaboration, oncology
TL;DR
Purple Biotech drops new IM1240 data with NCI, looks promising for cancer.
AI Summary
On September 4, 2025, Purple Biotech Ltd. announced new data supporting the unique design of their tri-specific antibody, IM1240. This announcement was made in collaboration with the National Cancer Institute (NCI). The data highlights the potential of CAPTN-3 in treating cancer.
Why It Matters
Positive data for IM1240 could advance Purple Biotech's pipeline and potentially offer new treatment options for cancer patients.
Risk Assessment
Risk Level: medium — Biotech drug development is inherently risky, with high failure rates and regulatory hurdles.
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer and subject of the announcement
- IM1240 (drug_candidate) — Tri-specific antibody discussed in the announcement
- CAPTN-3 (drug_candidate) — Design of the IM1240 antibody
- National Cancer Institute (NCI) (company) — Collaborator in the announcement
- September 4, 2025 (date) — Date of the press release
FAQ
What specific new data was announced regarding IM1240?
The filing states that new data was announced supporting the unique design of CAPTN-3 tri-specific antibody IM1240, but does not provide specific data points in this 6-K.
What is the role of the National Cancer Institute (NCI) in this announcement?
The NCI is collaborating with Purple Biotech on the announcement of the new data for IM1240.
What is the primary indication or target for IM1240?
The announcement mentions the 'unique design of CAPTN-3 Tri-Specific Antibody IM1240' in the context of cancer treatment, suggesting it is an oncology drug candidate.
When was this announcement made?
The announcement was made on September 4, 2025.
What is Purple Biotech Ltd.'s former name?
Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.
Filing Stats: 221 words · 1 min read · ~1 pages · Grade level 12.5 · Accepted 2025-09-04 07:03:02
Filing Documents
- ea0255984-6k_purple.htm (6-K) — 9KB
- ea025598401ex99-1_purple.htm (EX-99.1) — 16KB
- 0001213900-25-084262.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. September 4, 2025 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2